MindWalk Holdings Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $49.8M
- Price
- $1.06
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.00%
- Volume
- 182.4K
About
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Quick stats
Shares outstanding47.0M
Computed float—
Float / sharesUnknown
Cash runway (months)2.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001715925
Websitehttps://www.mindwalkai.com
AI Summary
AI-generated1/46
minorneutralother
Why the Next Edge in Antibody Discovery May Be What Labs Remember
This is a paid promotional newsletter from Wall Street Investor (wsi.news), compensated via Creative Direct Marketing Group to promote MindWalk Holdings (HYFT) and its multi-year Teva Australia ReefIQ agreement.
AMD appears only as a supporting mention: the article recycles previously reported Q2 2026 results ($11.5B revenue, up 50%) and the previously announced ~$8.2B all-stock World Labs acquisition, plus a MindWalk-authored GPU case study that AMD itself has not independently verified.
The publisher explicitly discloses the paid-promotion conflict of interest, states the article was reviewed and approved by MindWalk and CDMG, and reserves the right to trade MindWalk shares. No new AMD disclosure is contained in this piece.
Red flags
- paid advertisement / promotional newsletter disclosed at length
- publisher compensated to promote MindWalk (HYFT); article reviewed and approved by the promoted company
- publisher reserves right to buy and sell MindWalk shares at any time
- AMD performance claims in the MindWalk case study provided by MindWalk and not verified by AMD
- no new material information for AMD; figures are recycled from prior disclosures